{"id":44164,"date":"2022-05-20T13:01:29","date_gmt":"2022-05-20T11:01:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/grant-from-research-to-prevent-blindness-and-castle-biosciences-supports-medical-student-research-in-ocular-cancer\/"},"modified":"2022-05-20T13:01:29","modified_gmt":"2022-05-20T11:01:29","slug":"grant-from-research-to-prevent-blindness-and-castle-biosciences-supports-medical-student-research-in-ocular-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/grant-from-research-to-prevent-blindness-and-castle-biosciences-supports-medical-student-research-in-ocular-cancer\/","title":{"rendered":"\u00a0Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer"},"content":{"rendered":"
\n

\n\u00a0Research to Prevent Blindness and Castle Biosciences are partnering to provide new opportunities for medical students to pursue ocular cancer research \u00a0<\/i>\n<\/p>\n

NEW YORK & FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL<\/a> #CSTL<\/a>–Research to Prevent Blindness (RPB) and Castle Biosciences today announced that they are partnering to increase opportunities for medical students to gain research experiences, specifically in the field of ocular cancer. Ocular cancers, such as uveal melanoma (UM), are rare, affecting approximately 2,000 people per year in the U.S., but can be particularly devastating in terms of their effect on sight and on overall health. For these reasons, it is important to incentivize new research in this area and to bring new talent into the ocular cancer field.\n<\/p>\n

<\/a><\/p>\n

\nRPB and Castle Biosciences are providing funding for the RPB\/Castle Biosciences Medical Student Eye Research Fellowship in Ocular Cancer, which allows medical students to take a year off from medical school to devote time to the pursuit of a research project within an RPB-supported department of ophthalmology (see list at end of document). The award application<\/a> is now open; nomination forms are due June 15, 2022, and applications are due July 1, 2022.\n<\/p>\n

\n\u201cEffective treatment options are critical because, while not common, ocular cancer has such profoundly negative effects. We are so pleased to partner with Castle Biosciences to bring new talent into this area of research,\u201d said Brian F. Hofland, Ph.D., president of Research to Prevent Blindness. \u201cNot only will medical student researchers be conducting high quality, meaningful ocular cancer research under the guidance of a senior scientist\u2014therefore leading to opportunities for new knowledge in this area\u2014they will gain invaluable experience and skills that they will take with them into their future careers.\u201d\n<\/p>\n

\nIn 2022, the RPB\/Castle Biosciences Medical Student Eye Research Fellowship in Ocular Cancer will award one fellowship to a medical student focusing on a research project related to ocular cancer. The fellowship, which must take place prior to the student\u2019s third or fourth year of medical school, will be funded for one year with a $30,000 grant that will provide financial support in furtherance of the recipient’s ocular cancer research activities.\n<\/p>\n

\n\u201cAs a company founded on the desire to improve care for patients impacted by cancers with unmet clinical need, like uveal melanoma, this research fellowship is particularly meaningful to us at Castle,\u201d said Derek Maetzold, president and chief executive officer of Castle Biosciences. \u201cWhile the types of cancers that our diagnostic tests address have expanded over the years, our commitment to patients, research and innovation has remained the same, which is why we are proud to partner with RPB to offer this grant to a deserving student interested in making a difference in the field of ocular cancer.\u201d\n<\/p>\n

\nThe ophthalmology departments (by state) that are eligible to nominate students for this award are located at the following medical schools:\n<\/p>\n

\nCalifornia<\/b>\n<\/p>\n